Project Summary
With aging, hematopoietic stem and progenitor cells (HSPC) in the bone marrow (BM) accumulate somatic
mutations that may confer a proliferative advantage to the mutant cell; this enhanced clonal expansion gives rise
to mutant progeny cells which (i) comprise an outsized fraction of leukocytes in the peripheral blood and tissues
and (ii) typically have increased proinflammatory activity relative to normal leukocytes. In individuals with no
overt hematological malignancy, this age-related acquisition of somatic mutations that confer HSPC clonal
expansion advantage is designated clonal hematopoiesis of indeterminate potential (CHIP). CHIP affects >10%
of individuals older than 65 and predominantly involves genes encoding epigenetic regulators, such as, DNMT3A
(DNA methyltransferase 3A), which is the most commonly mutated gene in CHIP. CHIP has thus far been
conclusively linked with increased risk of hematologic malignancies and atherosclerotic cardiovascular disease.
We hypothesized that the generation in the BM and release in the circulation of CHIP-mutant leukocytes may
contribute to increased inflammatory destruction in tissues where they are recruited, such as the inflamed
periodontium. Our overall objective is to show that DNMT3A-driven CHIP increases the severity of periodontal
disease and to investigate the underlying mechanisms. Our hypothesis will be addressed in preclinical models
of CHIP and ligature-induced periodontitis in mice. CHIP will be modelled with Dnmt3aR878H/+ HSPC derived from
mice that harbor a mutation (R878H) that is equivalent to the human hotspot heterozygous mutation (R882H),
which causes a dominant negative loss of DNMT3A methylation activity. The experimental system involves
competitive BM transplantation with clinically relevant 10% CHIP-mutant cells (Dnmt3aR878H/+ CD45.2+ cells) and
90% wild-type CD45.1+ cells in CD45.1 recipient mice. Control CD45.1 recipient mice will be transplanted with
10% Dnmt3a+/+ CD45.2+ cells and 90% wild-type CD45.1+ cells, i.e., exclusively normal BM cells. In Specific Aim
1, we will investigate whether the expansion of Dnmt3a mutant clones is associated with exacerbation of
periodontal disease (‘to establish PHENOTYPE’). In Specific Aim 2, our objective is to establish a mechanistic
basis that can link DNMT3A-driven CHIP and periodontal disease (‘to establish MECHANISM’). In Specific Aim
3, we explore intervention approaches to block the expansion of Dnmt3a mutant clones and their impact on
periodontal disease (‘to develop THERAPY’). Our project can potentially implicate CHIP as a causal link between
aging and periodontal disease. If the hypothesis is confirmed and the proposed treatment is successful,
screening of the elderly for CHIP may identify individuals with increased risk for periodontal disease. Such
patients may benefit from preventive treatments aiming to block the aberrant expansion of CHIP mutant clones
and their harmful impact on periodontal disease (as well as on comorbidities that are also exacerbated by CHIP,
such as cardiovascular disease).